Basic information
Biomarker: PGI
Histology type: endometrial carcinoma
Cohort characteristics
Country: China
Region: Shanghai
Study type: Prospective study.
Followed up time :
Subgroup 1 name : EC
Subgroup 1 number: 72
Subgroup 2 name: normal endometrium (NE)
Subgroup 2 number: 32
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
30 | EC | 15 | normal endometrium (NE) | 15 |
Sample information
Conclusion: AMF/PGI is a potential therapeutic target in endometrial carcinoma.
Sample type : serum
Sample method: ELISA
Expression pattern : AMF/PGI
Disease information
Related information
Funtion description: AMF was highly expressed in human EC cell lines and endometrial tissue in EC patients. AMF knockdown reduced the growth, invasion, and migration of the EC cells both in vitro and in vivo. Exogenous PGI stimulation induces the promotion of EC cell migration, invasion, and proliferation, likely through MAPK-ERK1/2 signaling pathway, which suggests that AMF/PGI plays important roles in EC occurrence and progression.
Funtion Uniprot: In the cytoplasm, catalyzes the conversion of glucose-6-phosphate to fructose-6-phosphate, the second step in glycolysis, and the reverse reaction during gluconeogenesis (PubMed:28803808). Besides it's role as a glycolytic enzyme, also acts as a secreted cytokine: acts as an angiogenic factor (AMF) that stimulates endothelial cell motility (PubMed:11437381). Acts as a neurotrophic factor, neuroleukin, for spinal and sensory neurons (PubMed:3352745, PubMed:11004567). It is secreted by lectin-stimulated T-cells and induces immunoglobulin secretion (PubMed:3352745, PubMed:11004567).
UniProt ID: P06744
UniProt Link: https://www.uniprot.org/uniprotkb/P06744/entry
Biological function from UniProt: #Gluconeogenesis #Glycolysis
Molecular function from UniProt:
Subcellular UniProt: #Cytoplasm #Secreted
Alternative name from UniProt:
Catalytic activity: alpha-D-glucose 6-phosphate = beta-D-fructose 6-phosphate
Activity regulation: Strongly inhibited by erythrose 4-phosphate.
Recommended name: Glucose-6-phosphate isomerase
Gene name from HGNC: GPI (AMF, NLK)
HPA class: Cancer-related genes Disease related genes Enzymes Human disease related genes Metabolic proteins Plasma proteins Potential drug targets
AlphaFold DB: P06744
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P06744
HPA link: https://www.proteinatlas.org/ENSG00000105220-GPI
Tissue specificity RNA from HPA: Low tissue specificity
Tissue expression from HPA: Cytoplasmic expression at variable levels in most tissues.
Single cell type specificity Cell type enhanced (Late spermatids, Early spermatids)
Immune cell specificity: Low immune cell specificity
Subcellular summary HPA Located in Nucleoplasm, Plasma membrane, Cytosol (Single cell variability)
Cancer prognostic summary HPA Gene product is not prognostic
Pathology link: https://www.proteinatlas.org/ENSG00000105220-GPI/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000105220-GPI/pathology/endometrial+cancer
Phenotype ID: 613470
Disease: Hemolytic anemia, non-spherocytic, due to glucose phosphate isomerase deficiency (HA-GPID)
Note1: The disease is caused by variants affecting the gene represented in this entry
OMIM: 172400
OMIM link1: https://www.omim.org/entry/613470
OMIM link2: https://www.omim.org/entry/172400
HGNC ID: HGNC:4458
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4458